Goto K et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: Primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol 2023;41(31):4852-63. Abstract

Heymach JV et al. HER2-selective tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with advanced/metastatic solid tumors with HER2 alterations: A phase Ia dose-escalation study. J Clin Oncol 2025;43(11):1337-47. Abstract

Heymach JV et al. Zongertinib in patients with pretreated HER2-mutant advanced NSCLC: Beamion LUNG-1. AACR 2025;Abstract CT050.

Heymach JV et al. Zongertinib in previously treated HER2-mutant non-small-cell lung cancer. N Engl J Med 2025;392(23):2321-33. Abstract

Johnson ML et al. Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations. ASCO 2024;Abstract TPS8654.

Le X et al. Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study. ESMO 2025;Abstract LBA75.

Le X et al. SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations. ASCO 2025;Abstract TPS8648.

Nilsson MB et al. Trastuzumab deruxtecan resistance can be mediated by payload resistance or secondary extracellular ERBB2 mutations but sensitivity to HER2 tyrosine kinase inhibitors is maintained. AACR 2024;Abstract 5857.

Popat S et al. Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1. ESMO 2025;Abstract LBA74.

Wilding B et al. Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers. Cancer Discov 2025;15(1):119-38. Abstract